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ABSTRACT
Introduction: Adverse drug events (ADEs) are
common in older people and contribute significantly to
emergency department (ED) visits, unplanned
hospitalisations, healthcare costs, morbidity and
mortality. Many ADEs are avoidable if attention is
directed towards identifying and preventing
inappropriate drug use and undesirable drug
combinations. Tools exist to identify potentially
inappropriate prescribing (PIP) in clinical settings, but
they are underused. Applying PIP assessment tools to
population-wide health administrative data could
provide an opportunity to assess the impact of PIP on
individual patients as well as on the healthcare system.
This would open new possibilities for interventions to
monitor and optimise medication management on a
broader, population-level scale.
Methods and analysis: The aim of this study is to
describe the occurrence of PIP in Ontario’s older
population (aged 65 years and older), and to assess
the health outcomes and health system costs
associated with PIP—more specifically, the association
between PIP and the occurrence of ED visits,
hospitalisations and death, and their related costs. This
will be done within the framework of a population-
based retrospective cohort study using Ontario’s large
health administrative and population databases. Eligible
patients aged 66 years and older who were issued at
least 1 prescription between 1 April 2003 and 31
March 2014 (approximately 2 million patients) will be
included.
Ethics and dissemination: Ethical approval was
obtained from the Ottawa Health Services Network
Ethical Review Board and from the Bruyère Research
Institute Ethics Review Board. Dissemination will occur
via publication, presentation at national and
international conferences, and ongoing exchanges with
regional, provincial and national stakeholders, including
Strengths and limitations of this study
▪ The application of medication appropriateness
criteria (such as the STOPP/START and Beers’
criteria) to health administrative data provides a
unique opportunity to estimate the prevalence of
potentially inappropriate prescribing (PIP) at the
population level, with near-complete coverage
(our study population will comprise approxi-
mately 97% of Ontario’s seniors) and to assess
its impact, both human and economic, at the
individual and societal level.
▪ This study is expected to identify patient and
prescriber characteristics associated with a
higher likelihood of PIP, which could become the
target of interventions aimed at improving the
quality of prescribing.
▪ The use of health administrative data provides
high power to detect relevant associations at
comparatively lower cost than would be possible
using clinical data collected at the bedside.
▪ Several limitations may be encountered that are
inherent to studies relying on health administra-
tive data, including uncertainty surrounding
patient adherence to dispensed medications, the
unavailability of some clinical or diagnostic data,
and the absence of data for over-the-counter or
non-formulary medications. Each of these could
impact the estimate of true PIP in the population.
▪ Adverse effects of medication are known to be
broadly under-recognised and under-reported,
particularly in health administrative data, which
may limit this study’s ability to detect
medication-specific patient outcomes; for this
reason, more reliable outcome measures, such
as the occurrence of emergency department
visits, hospitalisation and mortality, will be used
as main outcomes for this study.
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the Ontario Drug Policy Research Network and the Ontario Ministry
of Health and Long-Term Care.
Trial registration number: Registered with clinicaltrials.gov
(registration number: NCT02555891).
INTRODUCTION
Background
Older people consume a disproportionate share of
medication compared with younger people. According
to a recent report from the Canadian Institute for
Health Information (CIHI) released in May 2014,
patients aged 65 years and older currently represent
15% of the Canadian population, yet their spending on
prescription medications accounts for over 40% of all
retail prescription drug sales and 60% of public drug
programme spending,1 three times the Canadian
average. Furthermore, nearly two-thirds (65.9%) of
Canadian patients aged 65 years and over had claims for
5 or more drug classes, and more than one-quarter
(27.2%) of seniors had claims for 10 or more drug
classes.2 Finally, older people are at higher risk of
adverse drug events (ADEs) than the rest of the popula-
tion.3 4 This elevated risk of ADE is due to various
factors, including higher numbers of medications pre-
scribed per person, increasing numbers of prescribers,
greater sensitivity to medication effects secondary to
natural age-related and disease-related changes in
pharmacokinetics, as well as higher baseline risk of
disease including higher likelihood of multimorbidity.3 4
The occurrence of ADE contribute signiﬁcantly to
more frequent emergency department (ED) visits,
unplanned hospitalisations,5 high healthcare costs,6 mor-
bidity and mortality in older populations.7 A recent
study showed that, of 600 older patients admitted to hos-
pital for an acute illness, 25% of them had one or more
ADEs prior to hospitalisation, of which two-thirds had
contributed to the hospitalisations.8 Of these events,
69% were deemed avoidable.
Potentially inappropriate prescribing (PIP), which
includes errors of co-mission as well as of omission, is
common in older people. Its likelihood increases with
the number of medications prescribed and it is often
associated with increased costs.9–11 A number of medica-
tion assessment tools exist to identify PIP that can lead
to ADE.9–19 Unfortunately, few of these tools have been
shown to reliably predict ADE,17 19 and although there
are a few studies showing associations between PIP and
adverse outcomes, their predictive validity needs to be
assessed further, particularly using large-scale national
health databases.
STOPP/START criteria
The STOPP/START criteria20 21 were developed by a
multidisciplinary team of geriatricians, pharmacists,
pharmacologists and primary care physicians and
consist, in the updated 2014 version, of 81 STOPP and
34 START criteria organised by physiological organ
system; STOPP criteria target errors of commission,
whereas START are concerned with errors of omission.
STOPP lists instances of PIP that should be avoided,
drug interactions and drugs that increase risk of falls,
while START lists instances of potential prescribing omis-
sions, where clinically indicated medicines are not pre-
scribed. The STOPP/START criteria were successfully
applied, with good inter-rater reliability, in a number of
settings, revealing rates of PIP of 22% in primary care
clinics, 35% in acute hospital settings and 60% in
nursing homes.12 16 20 22 In a validation study, screening
medications with the STOPP/START criteria was asso-
ciated with the subsequent use of fewer medications,
fewer incorrect doses and lower potential interactions.23
Beers’ criteria
The Beers’ criteria were the ﬁrst explicit criteria to be
published and have become widely used, particularly in
the USA where they originated.17 24 These criteria were
originally developed for use in nursing home patients;
they were modiﬁed three times, in 1997,25 200315 and
2012,26 and are now intended for use in all patients
above 65 years of age. Despite their popularity, the
Beers’ criteria have been criticised for including obso-
lete medications, as well as medications no longer avail-
able outside the USA, particularly in Europe,8 10 though
some of these issues have been addressed in the 2012
revision.26–29 They have also been criticised for not
being sufﬁciently inclusive of a number of common
instances of PIP.8 17 In particular, Beers only lists drugs
to avoid, but does not include other categories of PIP,
such as drug–drug and drug–disease interactions, drug
duplications or underuse and overuse of medications.17
Finally, Beers’ criteria have not been shown to be asso-
ciated with experiencing an ADE, discharge to a higher
level of care or in-hospital mortality.30
In a review of medication review tools performed
before the 2012 Beers’ update and the 2014 STOPP/
START update, STOPP/START were deemed ‘most
promising’, and were thought to have international
applicability.31
Assessing PIP at the population level
There are relatively few studies looking at the appropri-
ateness of prescribing at the population level. However,
population-level approaches using health administrative
data have the potential to assess the impact of inappro-
priate prescribing on large numbers of individual
patients as well as on healthcare systems.9
STOPP/START criteria were designed for use in con-
junction with patients’ clinical records; therefore, access
to patients’ full medical records and biochemical
(laboratory) data are necessary in order to deploy the
full set of criteria. As this information is usually not avail-
able in health administrative databases, a subset of
STOPP criteria (26 out of the 65 original STOPP cri-
teria) that did not require patient-level clinical data were
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identiﬁed by Cahir et al;9 START criteria could not be
used because they all require clinical data. The subset of
STOPP criteria was applied to population-level health
administrative prescription data to identify instances of
PIP, and to estimate their cost.9 The authors concluded
that the total healthcare expenditures on PIP amounted
to 9% of the overall drug expenditures of Ireland.9 They
were not able to assess the association of inappropriate
prescribing with patient outcomes (ED visits, hospitalisa-
tions or mortality) and their associated costs, as these
data were not available in their database.
Ontario possesses a comprehensive collection of
linked health administrative databases containing drug,
health services, socioeconomic and patients’ health
outcome data such as ED visits, hospitalisations and
deaths. These data sets offer opportunities to prospect-
ively assess the frequency of PIP, as well as associated out-
comes and costs for a whole population. In the present
study, we will apply a subset of the 2014 STOPP, START21
and 2012 Beers’ criteria26 to Ontario’s population-wide
health administrative data to describe the occurrence of
PIP in Ontario’s older population, and assess the health
outcomes and health system costs associated with it.
Evidence gaps to be filled
Using subsets of STOPP/START and, possibly, Beers’ cri-
teria applicable to health administrative data is a promis-
ing approach for the identiﬁcation of PIP in older
patients. Nonetheless, although PIP identiﬁed using
STOPP/START criteria have been shown to be asso-
ciated with ADEs and hospitalisations in clinical cohort
studies,8 32 33 a number of questions remain
unanswered, particularly with respect to their applica-
tion to population-wide health administrative data. In
this context, it remains to be established whether a
subset of STOPP/START and/or Beers’ criteria are pre-
dictive of relevant patient outcomes, such as the inci-
dence of ADE, ED visits, hospitalisations, composite
healthcare utilisation and mortality. Furthermore, it is
not clear whether such a subset of criteria could help
identify patient and prescriber characteristics associated
with a high likelihood of PIP, which could become the
target of interventions aimed at improving the quality of
prescribing.
To address these knowledge gaps, we will test three
hypotheses pertaining to the effects of PIP on Canada’s
senior population:
1. Instances of PIP are frequent and costly.
2. ED visits and hospitalisations are signiﬁcantly asso-
ciated with PIP.
3. The likelihood of PIP is associated with patient and
physician characteristics.
Identifying signiﬁcant associations for some or all of
the aforementioned hypotheses could provide evidence
to support important policy measures aimed at effect-
ively reducing PIP and its consequences on patients and
the healthcare system on a broader, population-level
scale.
METHODS AND ANALYSIS
Study design
We will conduct a population-based, retrospective,
dynamic (open) cohort study.
Definition of observation periods
The study period will span from 1 April 2002 to 31 March
2014. These dates were chosen based on availability for
all the required databases at the projected time of study
initiation (fall 2015); should recent data be available at
the time the study is conducted, the end of the study
period will be adjusted to allow inclusion of these data.
The accrual period is deﬁned at the period for ascertain-
ment of exposure (the occurrence of PIP); it starts
1 year after the start of the study period (ie, on 1 April
2003), and ends 1 year before the end of the study period
(ie, on 31 March 2013). This will allow a 1-year look-back
period preceding the ﬁrst included PIP, to describe
prior health services utilisation, medication use and
comorbidities (baseline risks), as well as a 1-year
follow-up period after the last possible PIP, to allow for
adequate follow-up of patient outcomes (see ﬁgure 1 for
a graphical illustration of study period, accrual period
and time frame for ascertainment of baseline risks,
exposures and outcomes).
Participants
Inclusion/exclusion criteria
Individuals eligible for participation in the study will
include all patients who were: (1) continuously eligible
for Ontario Health Insurance Plan (OHIP) coverage,
(2) issued at least one prescription (of any type) during
the accrual period (between 1 April 2003 and 31 March
2013), and (3) 66 years of age or older at the date of
ﬁrst dispensation during the accrual period; this is
necessary to ensure the availability of 1 year of back-
ground information on medication and health services
use for all patients. Instances of PIP will be identiﬁed
and catalogued during the accrual period.
The index date of a patient’s recruitment into the
study cohort will be the date of the ﬁrst prescription
dispensed following the beginning of the accrual period
(1 April 2003). Patients will be excluded if they do not
have a valid OHIP number. This includes individuals
whose healthcare is provided by other plans (eg, First
Nations people living on reserves, members of the
Canadian Armed Forces and refugee claimants) and is
therefore not captured by Institute for Clinical
Evaluative Sciences (ICES) data. Patients will also be
excluded if they were not OHIP-eligible for at least
1 year prior to the index date, or 1 year after the index
date, or if they do not have continuous OHIP coverage
between these two dates; this is necessary to ensure that
predictors and outcomes of PIP can be adequately cap-
tured. Patients not dispensed any prescription medica-
tion will not be included in the study. The selection of
the study cohort is shown graphically in ﬁgure 2. Based
on these criteria, we estimate that in excess of two
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Figure 1 Definition of
observation period (OHIP, Ontario
Health Insurance Plan).
Figure 2 Description of study cohort creation (PIP, potentially inappropriate prescribing).
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million patients will contribute data to our study (see
Methods section, ‘Validation and power’, for calculations
leading to this estimate).
Data sets
Patient data will be drawn from linked and de-identiﬁed
health administrative data sets housed at the ICES,
which will be accessed from the ICES@uOttawa site.
ICES is an independent, non-proﬁt organisation funded
by the Canadian province of Ontario’s Ministry of
Health and Long-Term Care (MOHLTC). ICES data-
bases contain information on hospital and outpatient
use of health services, demographic data and socio-
economic data for over 13 million Ontarians. All of
these data sets are linked using a patient-speciﬁc
encrypted identiﬁer. This study will use ﬁve general use
health services data sets.34 35
Ontario Drug Benefits Claims Database
The Ontario Drug Beneﬁt (ODB) programme provides
drug beneﬁts for all Ontario residents aged 65 and
older and those with disability/social assistance beneﬁts.
The Ontario Drug Beneﬁts Claims Database (ODBD)
contains a number of data related to prescription drugs,
including drug identiﬁcation number (DIN), quantity of
drugs provided, number of days supplied (which can be
used to compute the daily dose), itemised cost, dispens-
ing fee, long-term care indicators, the plan afﬁliated
with the prescription (eg, Seniors, Trillium, Ontario
Works, etc), the date the drug was dispensed, and
patient and prescriber identiﬁers (encrypted).
Additionally, ICES maintains a list linking DINs to their
associated drug and product names, subclass informa-
tion, pharmacological-therapeutic classiﬁcation group
codes, drug strength, route of administration, and ﬁrst
and last dispensing dates from the ODB.35
Discharge Abstract Database
The Discharge Abstract Database (DAD) captures all
acute care hospitalisations in Ontario dating back to
1988. Each row in the DAD records demographic, diag-
nostic, procedural and treatment information for a given
hospitalisation.35
Same Day Surgery Database
The Same Day Surgery Database (SDS) contains patient-
level data for day surgery institutions in Ontario. Every
record corresponds to one same-day surgery or proced-
ure stay.
National Ambulatory Care Reporting System
The National Ambulatory Care Reporting System
(NACRS) captures all visits to hospital EDs beginning in
2002. As with the DAD, each row of the NACRS contains
demographic, diagnostic, procedural and treatment
information for each emergency room visit.35
OHIP database
The OHIP database captures health services billing
claims paid by the OHIP to providers. Each row in the
OHIP database records the patient, provider and diagno-
sis/procedure being claimed for remuneration.
Care provider data will be obtained from the ICES
Physician Database (IPDP), which contains yearly informa-
tion about all physicians in Ontario, including physician
demographics (age, sex); specialty (functional and certi-
ﬁed); location; and measures of physician activity (bill-
ings, workload, types or services provided). The Client
Agency Program Enrolment (CAPE) database will be used to
determine the enrolment of an individual in a pro-
gramme with a speciﬁc practitioner and group. Birth
date and death date of every individual eligible for
Ontario health service will be obtained from the
Registered Persons Database (RPDB).35 In addition, we will
utilise ﬁve ICES-derived cohorts for case ascertainment
of diseases speciﬁed in the STOPP/STARTand Beers’ cri-
teria: asthma, diabetes, hypertension, chronic obstructive
pulmonary disease and congestive heart failure.
Exposure and outcomes
An overview of all variable deﬁnitions and units is pre-
sented in table form (table 1) and the variables are
expanded on in the following paragraphs.
Exposure variable
The main exposure variable will be the occurrence of the
ﬁrst PIP ever during the accrual period (see ﬁgure 3).
This will be used to quantify the association of a ﬁrst PIP
with an outcome (see ‘Primary outcome’ below).
A secondary exposure variable will be deﬁned to assess
the overall impact of PIP burden on patient outcomes:
we deﬁne this secondary outcome as the annualised
number of ﬁrst PIPs for any STOPP/STARTor Beers’ cri-
terion experienced by each patient during his or her
accrual period, a quantity which we term the ‘ﬁrst
(criterion-speciﬁc) PIP incidence density’. PIP incidence
density will be calculated separately for STOPP/START
and for Beers’ criteria. Since different patients will have
different accrual periods, this variable will be expressed
on an annualised basis, where the numerator is the total
number of ﬁrst criterion-speciﬁc PIPs experienced by
the patient, and the denominator is the person-time con-
tributed by the patient during his or her accrual period.
Since patients can only experience one ﬁrst PIP per cri-
terion, subsequent PIPs for the same criterion will not
be considered. This approach is made necessary because
the risk of outcome is likely to change with habituation
and prolonged exposure to a given PIP, and to reduce
the impact of patients with a large number of PIPs for a
given medication, or combination of medications.
To identify PIP, we will apply a subset of STOPP/
START and Beers’ criteria applicable to health adminis-
trative data by assessing both the patient’s drug history,
as recorded in the ODBD, and disease history as
obtained from linking DAD, SDS, NACRS, OHIP and
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Table 1 Variable definitions and units
Category Variable name Definition Scale Valid range/levels Units
Main
exposure
variable
First PIP ever Occurrence of the first PIP ever
experienced by a patient during
his/her study eligibility period
Dichotomous Yes or no 1 if PIP 0 if no
PIP
Secondary
exposure
variable
First
criterion-specific PIP
incidence density
Number of instances of first PIP
for each criterion experienced by
a patient during his/her eligibility
period divided by the duration of
the study eligibility period in
years (will be calculated
separately for STOPP/START
and Beers’ criteria).
Continuous 0 to unlimited Counts/year
Primary
outcome
variable
Time to any
outcome
Time between first PIP and first
of ER visit, hospitalisation or
death, occurring within the time
window for ‘PIP relevant
outcomes’ (usually up to
3 months after an instance of
PIP, but may be longer for some
criteria—see text for examples)
Ordinal 0–90 Days
Secondary
outcome
variables
Time to ER visit Time between first PIP and first
ER visit
Ordinal 0–90 Days
Time to
hospitalisation
Time between first PIP and first
hospitalisation
Ordinal 0–90 Days
Time to ADE Time to any diagnostic code for
an ADE
Ordinal 0–90 Days
Covariates Patient age Patient’s age at time of first PIP Continuous 66–116 Years
Patient sex Patient’s biological gender Dichotomous Male or female Male or female
Patient location Type of setting a patient lives in
at time of PIP
Dichotomous Long-term care vs
community setting
Long-term care
vs community
setting
Number of
prescribers
Number of prescribers who have
issued prescriptions for a patient
in year prior to the first PIP
Continuous 1 to unlimited Count
Number of
dispensing
pharmacists
Number of pharmacists from
whom a patient obtained
medication in the year prior to the
first PIP
Continuous 1 to unlimited Count
Polypharmacy Number of medications
concurrently in use at time of
prescription of a PIP
Continuous 1 to unlimited Count
SES Socioeconomic quintile attributed
to patient on the basis of his/her
census data and postal code
Ordinal Very low SES, low
SES, middle SES,
high SES, very
high SES
Quintile
Prior hospitalisations Number of hospital admissions
experienced by a patient in the
12 months preceding a PIP
Continuous 0 to unlimited Count
ER visit in past
6 months
Number of visits made to the
emergency room by a patient in
the 6 months preceding a PIP
Continuous 0 to unlimited Count
Comorbidities Deyo modification of Charlson
Comorbidity Index for a patient
calculated at the time of first PIP,
if patient was hospitalised in the
year prior to the first PIP; for
patients who were not
hospitalised, we will use the
Johns Hopkins ADG score
Continuous 0–32 NA
Continued
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ICES-derived cohorts as appropriate. Three members of
our team (a pharmacist (RH), a physician/epidemiolo-
gist (LMB) and a data analyst (ChC)) will identify this
subset of criteria using an iterative process. They will
assess the updated 2014 STOPP/START and 2012 Beers’
criteria for applicability to Ontario/ICES health adminis-
trative data, codify them using appropriate diagnostic
(ICD—International Classiﬁcation of Disease) and medi-
cation (DIN) codes, and convert them to SAS code for
use with ICES data. The resultant criterion selection and
coding will be reviewed by all co-authors and approved
by an iterative discussion and consensus process.
Primary outcome
Because ADEs are frequently under-recognised during
ED visits and hospitalisations,36 37 our study cohort is
also subject to substantial underestimation of ADEs. We
have therefore chosen to focus on reliably documented
clinical events, namely ED visits, hospitalisation and
death as our main outcome events, even though we rec-
ognise that not all will be causally related to a PIP. We
will control for this using multivariate methods. The
primary study end point is the time from the ﬁrst PIP
ever (during the accrual period) for any STOPP/START
or Beers’ criterion to the ﬁrst PIP-related event, which is
deﬁned as the ﬁrst all-cause ED visit, hospitalisation or
death occurring within 3 months after this PIP.
In secondary analyses, we will look at time to outcomes
following ﬁrst PIPs for individual criteria, which means
that patients can have more than one PIP-related event
(one for each criterion they fulﬁl; see ﬁgure 3). Each
type of PIP-related event (ie, ED visits, hospitalisations
and deaths) will also be considered as a separate
outcome and ADEs-related outcomes will be identiﬁed
using diagnostic codes. ED visits will be determined
from the NACRS database, hospitalisations from the
DAD database and death will be determined from the
RPDB. The relationship between these events and time
intervals is illustrated in ﬁgure 3, together with a few
examples of possible patient scenarios.
If the PIP includes a time-dependent deﬁnition (eg,
‘NSAID use >3 months’), the observation window will be
extended by 3 months beyond the speciﬁed minimum
exposure (thus, the outcome observation window would
be 6 months in the above example).
Censoring
Patients will be censored if they die or move out of the
province without experiencing an event, and their move
is captured by the RPDB. For the observation window
following an instance of PIP, we have chosen a 3-month
cut-off since we anticipate that the potential inﬂuence of
an instance of PIP would not likely last longer than this,
and probably would be shorter. If a patient experiences
an event other than death (ie, an ED visit or hospitalisa-
tion), that patient will be censored for the duration of
that event, but will remain in the study cohort after dis-
charge from the ED or hospital, as he/she may contrib-
ute further instances of PIP to the study base.
Covariates
Our analyses will control for the following covariates,
which are either known or perceived to be associated
with PIP and subject to their availability in the provincial
Table 1 Continued
Category Variable name Definition Scale Valid range/levels Units
Acuity of prior
hospitalisations
Whether a hospitalisation
occurring in the 12 months
preceding a PIP was coded as
‘acute’ or not in the Discharge
Abstract Database
Dichotomous Acute vs other 1 if acute 0 if
other
Discharge diagnosis Most responsible diagnosis for a
hospitalisation occurring in the
12 months preceding a PIP as
recorded in the Discharge
Abstract Database
Categorical ICD groups Diagnostic
groups
Prescribing
physician age
Physician age Continuous 20 to ?? years
Prescribing
physician sex
Physician’s biological gender Dichotomous Male or female Male or female
Prescribing
physician year of
graduation
Physician year of graduation Ordinal 1945 to ?? Year (date)
Prescribing
physician location
Physician location of practice
(rural vs urban)
Dichotomous Rural vs urban 0 rural, 1 urban
Type of prescribing
physician
Type of physician prescribing a
PIP for a given patient
Dichotomous Specialist vs family
physician
Specialist or
family MD
ADE, adverse drug event; ADG, Aggregated Diagnostic Group; ER, emergency room; ICD, International Classification of Disease; NA, not
available; PIP, potentially inappropriate prescribing; SES, socioeconomic status.
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health administrative databases (table 1 for a full list of
variable deﬁnitions): patient age, prescribing physician
sex, type of physician (specialist vs family physician),
physician year of graduation, practice location (urban vs
rural), whether a patient has a regular family physician,
number of prescribers in the year prior to a PIP,13
number of dispensing pharmacists during study eligibil-
ity period, patient location (long-term care vs commu-
nity setting)16 and polypharmacy (number of drugs used
concurrently by one patient at the time of prescription
of a PIP).38–42 Other patient-level factors known or sus-
pected of being associated with unplanned hospital
admissions and ED visits will also be included in the ana-
lyses as covariates: age,43 44 sex,44 socioeconomic status
(SES),44 45 rurality, comorbidity44 46 47 (calculated using
the Deyo modiﬁcation48 of the Charlson’s Comorbidity
Index (CCI)49), Johns Hopkins Adjusted Clinical
Groups (ACG) system,50 number of ED visits in
6 months prior to a PIP, number of prior hospitalisations
in the 12 months preceding a PIP,43 44 46 51–55 and
whether a patient has had a MedsCheck or
Pharmaceutical Opinion assessment performed in year
prior to ﬁrst PIP. We will use the postal code conversion
ﬁle to link the patient’s postal code to the dissemination
area, which is the smallest geographical census unit that
exists across all of Canada. We will then use census data
to determine the median household income of each dis-
semination area, which we will use as a proxy for individ-
ual SES. Linear interpolation will be used to infer
income for non-census years.
Figure 3 Time-to-event as a function of potentially inappropriate prescribing (PIP): possible patient scenarios, definition of
eligible exposure and of outcome observation time window.
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Statistical analyses
In order to address each of our three hypotheses, we
will ﬁt multivariable regression models. We will retain all
of the prespeciﬁed covariates in the model regardless of
statistical signiﬁcance, and we will validate our ﬁtted
models using modern bootstrap validation methods to
assess predictive performance and protect against
overﬁtting.56
The ‘skeleton’ tables of expected results for each of
the three hypotheses are shown in online supplementary
appendices A–C, respectively. In accordance with stand-
ard ICES procedures, data cell sizes containing fewer
than ﬁve counts will not be reported to protect
conﬁdentiality.
Hypothesis 1: Instances of PIP are frequent and costly.
We will describe the characteristics of the study cohort
using the parameters described in online supplementary
table 1A. To test hypothesis 1, we will ﬁrst apply the
STOPP/START and Beers’ criteria subset (as deﬁned in
the ‘Exposure variable’ section above) to our data by
identifying the occurrence of the ﬁrst PIP ever, and also,
in secondary analyses, by calculating the ﬁrst criterion-
speciﬁc PIP incidence density (see online supplemen-
tary table 1B), and make comparisons to other studies
that used STOPP/START and Beers. Subgroup analyses
will be conducted to estimate PIP incidence density in
long-term care and ambulatory patients (see online sup-
plementary table 1B), as these individuals are particu-
larly vulnerable to PIP.57
We will estimate the annual attributable risk58 of
adverse events by grouping patients’ ﬁrst PIP incidence
density (no PIP (reference), ≤1 PIP/year, 1≤2 PIP/year,
2≤3 PIP/year, 2≤3 PIP/year), and calculate HRs for
each group (see online supplementary table 1C).
Patients who did not experience a PIP will serve as the
reference category. We will apply the HRs for each
group to the proportion of the population attributable
to that group, using the frequency of events in the refer-
ence category as a baseline. This will yield an estimate of
the frequency of adverse events attributable to PIP, a
quantity that can also be expressed as an annual
number of adverse potential PIP-related events experi-
enced by Ontario seniors. We will conduct this calcula-
tion using all primary and secondary outcomes.
To estimate the overall cost of PIPs, we will combine
direct medication-related and direct non-medication
(healthcare utilisation)-related costs (see online supple-
mentary table 1D). Medication-related costs will be cal-
culated by aggregating all medications costs (including
medication costs and dispensing fees) associated with
each PIP in the study cohort. In instances where a PIP
involves more than one drug, only the cost of the
cheaper drug will be included, yielding a conservative
estimate; if a PIP involves the use of a high-dose drug
(with low-dose not considered a PIP), then we will con-
sider only the difference in price between high and low
dose as a potential saving. Healthcare utilisation costs
(direct non-medication costs) will include the costs of
ED visits and hospitalisations that are attributable to
each PIP, as deﬁned above by the attributable risk.
Hypothesis 2: ED visits and hospitalisations are signiﬁ-
cantly associated with PIP.
To test this hypothesis, we will use two complementary
approaches. First, a logistic regression will be performed
to assess the association between the occurrence of a
ﬁrst PIP ever and the likelihood of PIP-related events.
The reference category for this step will be ‘0 PIP’.
Second, a time-to-event analysis will be carried out to
address the following question: among patients experi-
encing PIP, does the likelihood of a PIP-related events
depend on the total number of ﬁrst PIPs by criteria
occurring before a given event? We will use ‘1’ as a refer-
ence category for this step. We will control for covariates
known or suspected of being associated with PIP (see
Covariates section above) by including them in our
models. Additional analyses that may be conducted, if
applicable (tables not shown): instrumental variables
regressions to adjust for potential unmeasured confoun-
ders, hierarchical models to address clustering, and sen-
sitivity analyses with different suboutcomes (time to ED
visit, time to hospitalisation, time to death, time to
ADE).
Hypothesis 3: The likelihood of inappropriate prescrib-
ing is associated with patient and physician
characteristics.
To test this hypothesis, we will identify each physician’s
PIP incidence density, calculated by dividing the
number of ﬁrst PIP per patient they issued by the total
number of ﬁrst prescriptions they provided over the
study period and then use a multilevel model to explore
the association of patient-level and physician-level covari-
ates with incidents. We will use intracluster correlation
coefﬁcients to estimate the variation in PIP prescribing
across prescribers and to identify which covariates
may explain this variation (see online supplementary
table 3A).59
Next, we will perform a multivariate linear regression
to describe provider and patient characteristics asso-
ciated with ﬁrst PIP incidence density (see online sup-
plementary table 3B), which will be ranked and
categorised into deciles and will act as the dependent
variable, with prescriber and patient characteristics
serving as independent variables. We expect to ﬁnd that
certain patient characteristics (eg, age, number of pre-
scribers) and prescriber characteristics (eg, rurality, sex,
age) are signiﬁcantly associated with PIP density, as iden-
tiﬁed in previous studies.13
Finally, we will describe the distribution of ﬁrst PIP
incidence density and then use a multilevel model to
explore the association of patient-level and physician-
level covariates and patient outcomes (ED visits, hospita-
lisations and mortality).
Cohort size and power
Dispensation of a ﬁrst prescription represents a patient’s
point of entry into our study population. Every year in
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Ontario, over 50 million prescriptions are dispensed and
recorded in the ODBD.35 The Ontario population in
2006 (mid-way through our study period) was approxi-
mately 12 600 000,60 of which about 14% were seniors,2
corresponding to 1 680 000 seniors. Given that this is a
dynamic population, with additions through ageing of
the population and patients moving into the province,
and losses through deaths and emigration, the actual
number of seniors in the database can be expected to
be higher, around 2–2.5 million patients. Given an
average annual number of medications per senior of
6.7,2 this would translate into approximately 13 million
medications being prescribed under ODB per year (with
more prescriptions, since there may be more than one
prescription for the same medication). Given our
10-year accrual period (1 April 2003 to 31 March 2013),
we could expect to have access to a total of over 130
million different instances of medications dispensed to
individual patients, and even more prescriptions.
As for event rates, applying a rate of PIP of 22% in
primary care found in earlier studies16 would result in
about 500 000 elderly patients experiencing PIPs per
year in Ontario (based on an estimated seniors popula-
tion of about 1.6 million). Since some patients will
experience more than one type of PIP during the study
accrual period, the number of eligible observations will
be greater.
This large cohort size, in terms of patients, number of
prescriptions and PIPs, ensures high statistical power to
detect any effect of even minor clinical importance.
However, we are in fact conducting a census of all eli-
gible patients—as opposed to sampling a population—
rendering a power calculation of little value.
Nonetheless, even if this represented a population
sample, we would have more than 90% power for the
vast majority of our planned analyses.
ETHICS AND DISSEMINATION
Registration
This cohort study is registered with clinicaltrials.gov
(registration number: NCT02555891)
Dissemination
Dissemination will occur via publication, presentations at
national and international conferences, professional net-
works, and ongoing exchanges with regional, provincial
and national stakeholders, including the Ontario Drug
Policy Research Network and the Ontario MOHLTC.
Statement of originality
To the best of our knowledge, the association of PIP
with patient outcomes, prescriber characteristics and
healthcare utilisation has not been studied in such a
large population-based study in any jurisdiction.
Ontario’s extensive holdings of linked health administra-
tive databases provide a unique opportunity to examine
the effects of PIP on a large scale.
Anticipated limitations
Our study is subject to several limitations inherent in
studies relying on health administrative data. We cannot
guarantee that patients regularly took the medications
dispensed to them, or that they adhered to the guidelines
for their use. Adherence to treatment can only be
assessed by comparing the date when an original pre-
scription was scheduled to expire with the dispensation
date of the renewal prescription. Some over-the-counter
medications included in the STOPP criteria subset (eg,
low-dose acetylsalicylic acid (ASA)) as well as medication
not covered by ODB plan (eg, sildenaﬁl—Viagra) are not
recorded in the ODBD and thus cannot be included. It is
also possible that some PIP identiﬁed by the STOPP cri-
teria subset in our database would actually be considered
appropriate were clinical or diagnostic data available to
support their use.61 That said, we anticipate that some
laboratory values housed in Ontario’s Laboratory
Integration System (OLIS) will become available to
researchers using ICES data within the coming year or
two. We expect that this will enable us to expand the
subset of STOPP/STARTand Beers’ criteria applicable to
health administrative data.62 Despite these limitations, we
are conﬁdent that our study will produce useful estimates
of the occurrence of PIP in Ontario’s senior population,
enable us to assess the health outcomes and health
system costs associated with PIP, and help evaluate an
existing measure aimed at mitigating its effects.
Safety and confidentiality considerations
Our study will make use of previously collected data,
and will not require any additional intervention or data
collection at the patient level. This study will be con-
ducted using Ontario health administrative databases
housed at the ICES, accessed from the ICES@uOttawa
site. ICES is an independent, non-proﬁt organisation
whose infrastructure funding and access to Ontario’s
large administrative databases is provided by the Ontario
MOHLTC. ICES links de-identiﬁed population-based
health information at the patient level in a way that
ensures privacy and conﬁdentiality of patients. ICES is
named as a section 45(1) Prescribed Entity in Ontario’s
Personal Health Information Protection Act (PHIPA).
Review, audit and approval of ICES’ policies, practices
and procedures related to data privacy and security are
performed triannually by the Information and Privacy
Commissioner of Ontario (IPC). This approval/review
document is available at http://www.ipc.on.ca. All of
these data sets are linked using a patient-speciﬁc
encrypted identiﬁer. This linkage is deterministic and
does not require any probabilistic methods. As per usual
ICES procedures, cell sizes <5 will not be reported to
address concerns about possible breaches in
conﬁdentiality.
Author affiliations
1Department of Family Medicine, University of Ottawa, Ottawa, Ontario,
Canada
10 Bjerre LM, et al. BMJ Open 2015;5:e010146. doi:10.1136/bmjopen-2015-010146
Open Access
group.bmj.com on August 15, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
2Bruyère Research Institute, Ottawa, Ontario, Canada
3ICES@ uOttawa, Ottawa, Ontario, Canada
4School of Epidemiology, Public Health and Preventive Medicine, University of
Ottawa, Ottawa, Ontario, Canada
5Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
6Economic and Social Research Institute, Trinity College Dublin, Dublin,
Ireland
7School of Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland
8School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada
9School of Pharmacy, University of Uppsala, Uppsala, Sweden
Acknowledgements The authors thank Justin Joshcko for helpful editorial
suggestions, as well as Matt Hogel and Chandra Landry for proofreading and
editorial suggestions at various stages in the creation of this manuscript; they
also thank Chandra Landry and Cody Black for invaluable help with formatting
references, tables and figures.
Contributors LMB conceived of the idea for this project, wrote the original
grant application (see online supplementary appendix E), updated and
adapted it to fit the requirements of the present protocol; she also generated
all the tables in the present manuscript, as well as in the online
supplementary material appendices. TR, CaC, CR, RH, BF, KT, ChC, SH, UG
and DGM provided expertise in their respective fields, all reviewed the
manuscript for important intellectual content and made suggestions for
improvement as appropriate; furthermore, they all approved the final version
of the manuscript for submission.
Funding This work was supported by the Canadian Institutes of Health
Research (CHIR), grant number 287245-HPM-BRUY-46830.
Competing interests CaC is the author of the study that applied a subset of
the 2008 STOPP criteria to an Irish prescription database.9 CR is a co-author
of the original STOPP/START criteria.20 21
Competing interests None declared.
Ethics approval Ottawa Health Services Network Ethical Review Board and
BruyereBruyère Research Institute Ethics Review Board (see online
supplementary appendix D).
Provenance and peer review Not commissioned; peer reviewed for ethical
and funding approval prior to submission.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Canadian Institute for Health Information. Drug use among seniors
on public drug programs in Canada, 2012. Ottawa, Ontario, 2014.
2. Canadian Institute for Health Information (CIHI). Drug use among
seniors on public drug programs in Canada, 2002 to 2008. Ottawa,
Ontario: CIHI, 2010.
3. Merle L, Laroche M-L, Dantoine T, et al. Predicting and preventing
adverse drug reactions in the very old. Drugs Aging
2005;22:375–92.
4. Hutchison LC, O’Brien CE. Changes in pharmacokinetics and
pharmacodynamics in the elderly patient. J Pharm Pract
2007;20:4–12.
5. Laroche ML, Charmes JP, Nouaille Y, et al. Is inappropriate
medication use a major cause of adverse drug reactions in the
elderly? Br J Clin Pharmacol 2007;63:177–86.
6. Wu C, Bell C, Wodchis W. Incidence and economic burden of
adverse drug reactions among elderly patients in Ontario emergency
departments: a retrospective study. Drug Saf 2012;35:769–81.
7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug
reactions in hospitalized patients: a meta-analysis of prospective
studies. JAMA 1998;279:1200–5.
8. Hamilton H, Gallagher P, Ryan C, et al. Potentially inappropriate
medication defined by STOPP criteria and the risk of adverse drug
events in older hospitalized patients. Arch Intern Med
2011;171:1013–19.
9. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate
prescribing and cost outcomes for older people: a national
population study. Br J Clin Pharmacol 2010;69:543–52.
10. Goltz L, Kullak-Ublick GA, Kirch W. Potentially inappropriate
prescribing for elderly outpatients in Germany: a retrospective claims
data analysis. Int J Clin Pharmacol Ther 2012;50:185.
11. Shah RB, Gajjar BM, Desai SV. Evaluation of the appropriateness of
prescribing in geriatric patients using Beers criteria and Phadke’s
criteria and comparison thereof. J Pharmacol Pharmacother
2011;2:248–52.
12. Byrne S, Ryan C, O’Mahony D, et al. Inappropriate prescribing in the
elderly: a review of primary care and nursing home prescriptions.
Int J Pharm Pr 2008;16(Suppl 1):A36–7.
13. Dhalla IA, Anderson GM, Mamdani MM, et al. Inappropriate
prescribing before and after nursing home admission. J Am Geriatr
Soc 2002;50:995–1000.
14. Dimitrow MS, Airaksinen MS, Kivelä SL, et al. Comparison of
prescribing criteria to evaluate the appropriateness of drug treatment
in individuals aged 65 and older: a systematic review. J Am Geriatr
Soc 2011;59:1521–30.
15. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria
for potentially inappropriate medication use in older adults: results of
a US consensus panel of experts. Arch Intern Med 2003;163:2716.
16. O’Mahony D, Gallagher P, Ryan C, et al. STOPP & START criteria:
a new approach to detecting potentially inappropriate prescribing in
old age. Eur Geriatr Med 2010;1:45–51.
17. Page RL, Linnebur SA, Bryant LL, et al. Inappropriate prescribing in
the hospitalized elderly patient: defining the problem, evaluation
tools, and possible solutions. Clin Interv Aging 2010;5:75–87.
18. Ryan C, O’Mahony D, Kennedy J, et al. Appropriate prescribing in
the elderly: an investigation of two screening tools, Beers criteria
considering diagnosis and independent of diagnosis and improved
prescribing in the elderly tool to identify inappropriate use of
medicines in the elderly in primary care in Ireland. J Clin Pharm
Ther 2009;34:369–76.
19. Patterson S, Hughes C, Kerse N, et al. Interventions to improve the
appropriate use of polypharmacy for older people. Cochrane
Database Syst Rev 2012;5:CD008165.
20. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older
Persons’ potentially inappropriate Prescriptions): application to
acutely ill elderly patients and comparison with Beers’ criteria. Age
Ageing 2008;37:673–9.
21. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria
for potentially inappropriate prescribing in older people: version 2.
Age Ageing 2014;16:1–6.
22. Ryan C, O’Mahony D, Kennedy J, et al. Potentially inappropriate
prescribing in an Irish elderly population in primary care. Br J Clin
Pharmacol 2009;68:936–47.
23. Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially
inappropriate prescribing for elderly patients: a randomized
controlled trial using STOPP/START criteria. Clin Pharmacol Ther
2011;89:845–54.
24. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for
determining inappropriate medication use in nursing home residents.
Arch Intern Med 1991;151:1825.
25. Beers MH. Explicit criteria for determining potentially inappropriate
medication use by the elderly: an update. Arch Intern Med
1997;157:1531–6.
26. American Geriatrics Society 2012 Beers Criteria Update Expert
Panel. American Geriatrics Society updated Beers Criteria for
potentially inappropriate medication use in older adults. J Am Geriatr
Soc 2012;60:616–31.
27. Marcum ZA, Hanlon JT. Commentary on the New American Geriatric
Society Beers Criteria for potentially inappropriate medication use in
older adults. Am J Geriatr Pharmacother 2012;10:151.
28. Resnick B, Pacala JT. 2012 Beers Criteria. J Am Geriatr Soc
2012;60:612–13.
29. Fick DM, Semla TP. 2012 American Geriatrics Society Beers
Criteria: new year, new criteria, new perspective. J Am Geriatr Soc
2012;60:614–15.
30. Page RL, Ruscin JM. The risk of adverse drug events and
hospital-related morbidity and mortality among older adults with
potentially inappropriate medication use. Am J Geriatr Pharmacother
2006;4:297–305.
31. Levy H, Marcus E, Christen C. Beyond the beers criteria:
a comparative overview of explicit criteria. Ann Pharmacother
2010;44:1968–75.
32. Gracía-Gollarte F, Júlvez J, Ferrero-López I, et al. An educational
intervention on drug use in nursing homes improves health
outcomes resource utilization and reduces inappropriate drug
prescription. J Am Med Dir Assoc 2014;15:885–91.
Bjerre LM, et al. BMJ Open 2015;5:e010146. doi:10.1136/bmjopen-2015-010146 11
Open Access
group.bmj.com on August 15, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
33. Frankenthal D, Lerman Y, Kalendaryev E. Intervention with the
screening tool of older persons potentially inappropriate
prescriptions/screening tool to alert doctors to right treatment criteria
in elderly residents of a chronic geriatric facility: a randomized
clinical trial. J Am Geriatr Soc 2014;62:1658–65.
34. Bronskill S, Carter M, Costa A, et al. Aging in Ontario: an ICES
chartbook of health service use by older adults—technical report.
Toronto, 2010.
35. Institute for Clinical Evaluative Sciences (ICES). Health services
data. 2011. http://www.ices.on.ca/webpage.cfm?site_id=1&org_
id=26&morg_id=0&gsec_id=5314&item_id=5326
36. Hohl C, Zed P, Brubacher J, et al. Do emergency physicians
attribute drug-related emergency department visits to medication-
related problems? Ann Emerg Med 2010;55:493–502.
37. Hohl C, Robitaille C, Lord V, et al. Emergency physician
recognition of adverse drug-related events in elder patients
presenting to an emergency department. Acad Emerg Med 2005;12:
197–205.
38. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients.
Am J Geriatr Pharmacother 2007;5:345–51.
39. Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for
adverse drug events in hospitalized patients. ADE Prevention Study
Group. Arch Intern Med 1999;159:2553–60.
40. Carey IM, De WS, Harris T, et al. What factors predict potentially
inappropriate primary care prescribing in older people? Analysis of
UK primary care patient record database. Drugs Aging
2008;25:693–706.
41. Evans RS, Lloyd JF, Stoddard GJ, et al. Risk factors for adverse
drug events: a 10-year analysis. Ann Pharmacother
2005;39:1161–8.
42. Kanjanarat P, Winterstein AG, Johns TE, et al. Nature of preventable
adverse drug events in hospitals: a literature review. Am J Heal Syst
Pharm 2003;60:1750–9.
43. Boult C, Dowd B, McCaffrey D, et al. Screening elders for risk of
hospital admission. J Am Geriatr Soc 1993;41:811–17.
44. Anderson GF, Steinberg EP. Predicting hospital readmissions in the
Medicare population. Inquiry 1985;22:251–8.
45. Weissman J, Stern R, Epstein A. The impact of patient
socioeconomic status and other social factors on readmission:
a prospective study in four Massachusetts hospitals. Inquiry
1994;31:163–72.
46. Krumholz HM, Parent EM, Tu N, et al. Readmission after
hospitalization for congestive heart failure among Medicare
beneficiaries. Arch Intern Med 1997;157:99–104.
47. Chin MH, Goldman L. Correlates of early hospital readmission or
death in patients with congestive heart failure. Am J Cardiol
1997;79:1640–4.
48. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity
index for use with ICD-9-CM administrative databases. J Clin
Epidemiol 1992;45:613–19.
49. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 1987;40:373–83.
50. Austin PC, van Walraven C, Wodchis WP, et al. Using the Johns
Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in
a general adult population cohort in Ontario, Canada. Med Care
2011;49:932–9.
51. Phillips RS, Safran C, Cleary PD, et al. Predicting emergency
readmissions for patients discharged from the medical service of a
teaching hospital. J Gen Intern Med 1987;2:400–5.
52. Reed RL, Pearlman RA, Buchner DM. Risk factors for early unplanned
hospital readmission in the elderly. J Gen Intern Med 1991;6:223–8.
53. Corrigan JM, Martin JB. Identification of factors associated with
hospital readmission and development of a predictive model. Health
Serv Res 1992;27:81–101.
54. Colledge NR, Ford MJ. The early hospital readmission of elderly
people. Scott Med J 1994;39:51–2.
55. van Walraven C, Mamdani M, Fang J, et al. Continuity of care and
patient outcomes after hospital discharge. J Gen Intern Med
2004;19:624–31.
56. Harrell F. Regression modeling strategies. 2nd edn. Springer
International Publishing, 2015.
57. Bronskill S, Gill S, Paterson J, et al. Exploring variation in rates of
polypharmacy across long term care homes. J Am Med Dir Assoc
2012;13:309.e15–21.
58. Armitage G, Berry P. Statistical methods in medical research.
Oxford: Blackwell Scientific Publishing, 1994.
59. Guthrie B, McCowan C, Davey P, et al. High risk prescribing in
primary care patients particularly vulnerable to adverse drug events:
cross sectional population database analysis in Scottish general
practice. BMJ 2011;342:d3514.
60. Canada S. 2006 Census highlights: factsheet 1. 2009. http://www.
fin.gov.on.ca/en/economy/demographics/census/cenhi06-1.html
61. Ryan C, O’Mahony D, O’Donovan DÓ, et al. A comparison of the
application of STOPP/START to patients’ drug lists with and without
clinical information. Int J Clin Pharm 2013;35:230–5.
62. Institute for Clinical Evaluative Sciences (ICES). ICES internal
communication, April 7 2015. 2015.
12 Bjerre LM, et al. BMJ Open 2015;5:e010146. doi:10.1136/bmjopen-2015-010146
Open Access
group.bmj.com on August 15, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
databases
criteria in large health administrative 
subsets of the STOPP/START and Beers'
population-based cohort study applying 
outcomes in Ontario's older population: a
prescribing (PIP) and predicting patient 
Assessing potentially inappropriate
Hawken, Ulrika Gillespie and Douglas G Manuel
Halil, Barbara Farrell, Kednapa Thavorn, Christina Catley, Steven 
Lise M Bjerre, Timothy Ramsay, Catriona Cahir, Cristín Ryan, Roland
doi: 10.1136/bmjopen-2015-010146
2015 5: BMJ Open 
 http://bmjopen.bmj.com/content/5/11/e010146
Updated information and services can be found at: 
These include:
Material
Supplementary
 146.DC1.html
http://bmjopen.bmj.com/content/suppl/2015/11/25/bmjopen-2015-010
Supplementary material can be found at: 
References
 #BIBLhttp://bmjopen.bmj.com/content/5/11/e010146
This article cites 54 articles, 6 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (368)Pharmacology and therapeutics
 (1067)Health services research
 (215)Geriatric medicine
 (1626)Epidemiology
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on August 15, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on August 15, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
